Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial of Sequential Re-Radiochemotherapy and Pembrolizumab Versus Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive HNSCC (CPS≥1)

NCT07026474 is registered in ClinicalTrials.gov with Universität des Saarlandes as lead sponsor.

NCT NCT07026474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07026474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial of Sequential Re-Radiochemotherapy and Pembrolizumab Versus Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive HNSCC (CPS≥1)
Lead sponsor
Universität des Saarlandes
Phase
Phase 3
Overall status
Recruiting
Start date
October 30, 2025
Completion date
December 31, 2032
Enrollment
214 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent head and neck squamous cell carcinoma